Jerry Carter

Lose 26 pounds in just 3 injections!

Obesity is a heterogeneous chronic disease that has become an extremely prevalent public health problem and one of the greatest threats to human health and well-being in the 21st century. Obesity-related complications place an enormous burden on patients and healthcare systems worldwide, and there is an urgent need for effective and safe obesity treatments.

Enteric insulin-based drugs (e.g., GLP-1, GIP) have been used in type 2 diabetes and obesity treatments, such as simethicone (GLP-1 receptor agonist) and tilprotectin (dual GLP-1/GIP receptor agonist), which not only bring about significant weight loss but also improve cardiovascular health. However, the need for enhanced efficacy and improved pharmacokinetics to reduce the frequency of administration and side effects remains high for patients.

On February 5, 2024, researchers at Amgen published an article in the journal Nature Metabolism entitled "A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings".

AMG 133, a bispecific molecule developed by Amgen that combines a fully human monoclonal anti-GIPR antibody conjugated to two GLP-1 analog agonist peptides, was shown to be effective in reducing body weight and improving metabolic health in male obese mice and cynomolgus monkeys.